Privium Fund Management B.V. Purchases 36,500 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Privium Fund Management B.V. boosted its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 14.4% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 289,804 shares of the biopharmaceutical company’s stock after acquiring an additional 36,500 shares during the quarter. Ultragenyx Pharmaceutical accounts for about 1.6% of Privium Fund Management B.V.’s investment portfolio, making the stock its 14th largest position. Privium Fund Management B.V. owned 0.30% of Ultragenyx Pharmaceutical worth $8,717,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Covestor Ltd boosted its holdings in shares of Ultragenyx Pharmaceutical by 26.0% in the 3rd quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 369 shares in the last quarter. Elevation Point Wealth Partners LLC bought a new stake in Ultragenyx Pharmaceutical in the 2nd quarter worth approximately $55,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Ultragenyx Pharmaceutical by 18.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,652 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 557 shares in the last quarter. CWM LLC grew its position in Ultragenyx Pharmaceutical by 1,171.2% during the second quarter. CWM LLC now owns 4,144 shares of the biopharmaceutical company’s stock valued at $151,000 after acquiring an additional 3,818 shares during the last quarter. Finally, Osaic Holdings Inc. raised its stake in shares of Ultragenyx Pharmaceutical by 4,371.7% during the second quarter. Osaic Holdings Inc. now owns 4,740 shares of the biopharmaceutical company’s stock worth $172,000 after acquiring an additional 4,634 shares in the last quarter. Institutional investors own 97.67% of the company’s stock.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 3,081 shares of the stock in a transaction on Wednesday, December 10th. The stock was sold at an average price of $36.38, for a total value of $112,086.78. Following the completion of the transaction, the chief financial officer owned 95,146 shares in the company, valued at approximately $3,461,411.48. This represents a 3.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 5.50% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on RARE. Leerink Partners dropped their target price on Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Tuesday, December 30th. HC Wainwright dropped their price objective on Ultragenyx Pharmaceutical from $80.00 to $60.00 and set a “buy” rating for the company in a research note on Monday, January 5th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, January 21st. Barclays lowered their price target on shares of Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating for the company in a report on Monday, November 24th. Finally, Wells Fargo & Company cut their price target on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating on the stock in a report on Tuesday, December 30th. Sixteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $72.29.

Ultragenyx Pharmaceutical Trading Down 0.8%

Shares of RARE opened at $24.07 on Friday. Ultragenyx Pharmaceutical Inc. has a 1-year low of $18.41 and a 1-year high of $46.50. The firm’s 50-day moving average price is $29.03 and its 200-day moving average price is $29.96. The firm has a market capitalization of $2.32 billion, a price-to-earnings ratio of -4.05 and a beta of 0.15.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.58). Ultragenyx Pharmaceutical had a negative return on equity of 414.17% and a negative net margin of 91.95%.The company had revenue of $159.93 million during the quarter, compared to analysts’ expectations of $167.42 million. During the same quarter last year, the business earned ($1.40) earnings per share. The business’s quarterly revenue was up 14.6% on a year-over-year basis. On average, research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.